Effects of berberine-containing vs clarithromycin-containing quadruple therapy on intestinal microbiota during Helicobacter pylori eradication

doi:10.3748/wjg.122243

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 43

This Article

(3)

(0)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 21, 2026; 32(43): 122243
Published online Nov 21, 2026. doi: 10.3748/wjg.122243

Table 1 Comparison of 14-day Helicobacter pylori eradication quadruple regimens containing berberine

Ref.	Design	Number		Intervention		Berberine dose	Outcome	Eradiation rate
Ref.	Design	Exp	Ctrl	Exp	Ctrl	Berberine dose	Outcome	Exp	Ctrl
Present study	Pilot RCT	21	20	BBR, AMX, OME, BIS	CLA, AMX, OME, BIS	300 mg TID	¹³C-UBT	80.95%	75.00%
Pang et al[17]	RCT	274	274	BBR, MIN, ESO, CBP	CLA, AMX, ESO, CBP	500 mg BID	¹³C-UBT/¹⁴C-UBT	79.90%	77.40%
Zhang et al[14]	RCT	329	329	BBR, AMX, ESO, CBP	TET, FUR, ESO, CBP	300 mg TID	¹³C-UBT/¹⁴C-UBT/HpSAT	76.30%	77.50%
Zhang et al[18]	RCT	308	304	BBR, AMX, CLA, ESO	CLA, AMX, ESO, CBP	500 mg BID	¹³C-UBT	86.40%	90.10%

RCT: Randomized controlled trial; Exp: Experiment group; Ctrl: Control group; BBR: Berberine; AMX: Amoxicillin; OME: Omeprazole; BIS: Bismuth potassium citrate; CLA: Clarithromycin; MIN: Minocycline; ESO: Esomeprazole; CBP: Colloidal bismuth pectin; TET: Tetracycline; FUR: Furazolidone; TID: Three times daily; BID: Twice daily; ¹³C-UBT: ¹³C-urea breath test; ¹⁴C-UBT: ¹⁴C-urea breath test; HpSAT: Helicobacter pylori stool antigen test.

Full Size Table

Citation: Cai TW, Chen ZK, Lv ZY, Jiang WJ, Sun YY, Jin LX, Xia CM, Li QQ, Chen X. Effects of berberine-containing vs clarithromycin-containing quadruple therapy on intestinal microbiota during Helicobacter pylori eradication. World J Gastroenterol 2026; 32(43): 122243
URL: https://www.wjgnet.com/1007-9327/full/v32/i43/122243.htm
DOI: https://dx.doi.org/10.3748/wjg.122243

Cai TW, Chen ZK, Lv ZY, Jiang WJ, Sun YY, Jin LX, Xia CM, Li QQ, Chen X. Effects of berberine-containing vs clarithromycin-containing quadruple therapy on intestinal microbiota during Helicobacter pylori eradication. World J Gastroenterol 2026; 32(43): 122243 [DOI: 10.3748/wjg.122243]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.